We investigated the feasibility of local treatment or tumor vaccination with a herpes simplex virus (HSV) type 1-defective vector. The vector was engineered to express murine interferon-␥ (IFN-␥) for experimental gene therapy against mouse glioma Rous sarcoma virus (RSV). The murine IFN-␥ gene was driven by the cytomegalovirus promoter. The helper virus (tsk) was thermosensitive; consequently, this vector could only proliferate at 31°C. A high level of murine IFN-␥ expression was confirmed in vitro and in vivo by immunohistochemistry using anti-mouse IFN-␥ monoclonal antibody. This engineered vector (dvHSV/ MuIFN-␥) inhibited the proliferation of mouse glioma RSV cells in vitro, and an intratumoral (i.t.) local injection of the vector caused i.t. necrosis in vivo. The immunological effect of dvHSV/MuIFN-␥ was also examined in a mouse glioma RSV cell implantation model. A subcutaneous (s.c.) implant of 1 ϫ 10 6 mouse glioma RSV cells after treatment with dvHSV/MuIFN-␥ was rejected. However, the implant after treatment with an engineered HSV-defective vector containing an antisense nucleotide sequence of the murine IFN-␥ gene was not rejected. In addition, in another group of mice in which RSV cells treated with dvHSV/MuIFN-␥ were implanted into a femoral (s.c.) region and nontreated RSV cells were implanted into a contralateral femoral (s.c.) region, the implanted RSV cells were rejected. The rejection of the implanted mouse glioma RSV was blocked by anti-asialo GM1, which was known to inhibit natural killer cell activity. These results revealed that the HSV-defective vector could realize a high efficiency of transfection to glioma cells through short-time treatment, and that the IFN-␥ gene transferred to the cells had the effect of tumor vaccination, which was suggested be related to natural killer cells. In conclusion, dvHSV/MuIFN-␥ may be useful for the gene therapy of malignant glioma through either i.t. local injection or a practical tumor vaccination with ex vivo gene transfer.
M alignant glioma is the most common malignant primary brain tumor. Despite conventional therapies such as surgery, chemotherapy, and radiation, these therapeutic results remain unsatisfactory. The median survival rate of patients with the most malignant glioma, glioblastoma, is Ͻ1 year; their 5-year survival is Յ5.5%. [1] [2] [3] Therefore, the potential utility of gene therapy for the treatment of malignant glioma has been proposed. 4 -6 However, significant usefulness of suicide gene therapy using retrovirus vector to carry the herpes simplex virus (HSV) thymidine kinase gene and ganciclovir has not been proved. Other viral vectors, including herpes simplex vector, 5 adenoviral vector, 7 and adenoassociated vector, 6 have been used for malignant glioma gene therapy. In addition, liposome transfection as a gene transfer method in place of viral vectors for experimental glioma was reported. 8 Recently, immunogene therapies have been tried for malignant gliomas with transfection of tumor cells with cytokine genes. 9, 10 After treatment for malignant glioma, recurrent disease often occurs locally or with cerebrospinal fluid dissemination, leading to death. Leptomeningeal dissemination of malignant glioma is a target for immunogene therapy. Interferon-␥ (IFN-␥) plays an important role in immune responses against neoplasia, in which it attacks tumor cells both indirectly and directly. Therefore, IFN-␥ is an important cytokine in the therapeutic approach to malignant tumors. 11 Immunotherapy and immunogene therapy using IFN-␥ have been intensely investigated. Exogenous expression of IFN-␥ gene resulted in reduced tumorigenicity. 12 IFN-␥ gene transfer into tumor cells generated potent and long-lasting antitumor immunity. 13 After the IFN-␥-producing gene transfer, the survival period of tumor-bearing mice was prolonged.
14 IFN-␥ gene-inserted tumor cells showed the effect of antimetastatic vaccination. 15 In addition, the mechanism of rejection induced by tumor cell-IFN-␥ gene transfer has been investigated. 16 HSV type 1-defective vector is easily operated to integrate an expression gene and could have a deterious effect on neurons. Ganciclovir treatment with HSVdefective vectors expressing thymidine kinase resulted in significantly decreased tumor size. 17 Recently, a metastatic brain tumor model of melanoma was successfully treated through the method of tumor vaccination. 18 Therefore, we engineered a neurotrophic HSV-defective vector expressing IFN-␥ with the aims of tumor killing and tumor vaccination therapy.
MATERIALS AND METHODS

Construction of amplicon plasmid of HSV-defective vector for expression of murine IFN-␥
The amplicon plasmid, which is a part of the HSV-defective vector, 19, 20 essentially contains a eukaryotic transcription unit and cis-acting HSV sequences and encodes both an origin site for DNA replication and a cleavage/packaging signal. 21 The plasmid pHCL contains the bacterial lacZ gene under the control of the human cytomegalovirus (CMV) immediate early promoter. 13 The amplicon plasmid of the HSV-defective vector (pHCMV/MuIFN-␥) expressing murine IFN-␥ was kindly provided by Dr. T. Sakata of the Shionogi Institute (Osaka, Japan). This plasmid, for which the murine IFN-␥ gene was driven by the CMV promoter, was generated as follows: pHCL was digested with HindIII and SalI to remove the bacterial lacZ gene and ligated to simian virus 40 polyadenylation signal, which was released from pRep4 (Invitrogen, Carlsbad, Calif) digestion with HindIII (Takara, Shiga, Japan) and XhoI (Takara). The resultant plasmid, pHCMV-pA, has several cloning sites for expression of a foreign gene. A 0.93-kilobase (kb) BbsI-SmaI fragment of murine IFN-␥ cDNA was isolated from plasmid IFN-␥ and inserted into a HindIII site downstream from the CMV promoter using blunt-end ligation. As a control vector (dvHSV/Mu.anti-IFN-␥), the antisense of the full-length of the murine IFN-␥ gene was inserted instead of the murine IFN-␥ gene (Fig 1) .
Generation of HSV-defective vector for expression of murine IFN-␥ An HSV-defective vector composed of the amplicon pHCMV/ MuIFN-␥ and the helper virus tsk was generated as described previously. 20 Plaque assay of the resulting stock at a nonpermissive temperature (37°C) demonstrated that the reversion of the temperature-sensitive helper virus tsk to wild-type virus occurred at a rate of Ͻ10 Ϫ7 /mL, which is consistent with previous observations. This viral vector (dvHSV/MuIFN-␥) titer was estimated from the ratio of amplicon to helper virus DNA as described previously.
21,22
Amplification of dvHSV/MuIFN-␥ Proliferating Vero cells (derived from African green monkey kidneys and provided by the Kihara Institute for Biological Research, Yokohama City University) were transfected with dvHSV/MuIFN-␥ in minimal essential medium (MEM) (Life Technologies, New York, NY) supplemented with 5% fetal calf sera (Life Technologies) at 31°C in 5% CO 2 . One-third of the culture medium of Vero cells was replaced with the MEM containing 1 ϫ 10 7 plaque-forming units (PFU) of dvHSV/ MuIFN-␥ and incubated at 31°C in 5% CO 2 . With repetitions of the procedure, 100 mL of the supernatant containing dvHSV/MuIFN-␥ was accumulated. The cultured Vero cells floating in the culture medium were disrupted with an ultrasonic cell crusher. After a freeze-thaw/sonication regimen, the cell debris was removed by low-speed centrifugation (2000 ϫ g for 10 minutes at 4°C). The supernatant containing dvHSV/ MuIFN-␥ was stocked at Ϫ80°C. The titer of viral stock was 5 ϫ 10 6 PFU/mL. dvHSV/Mu.anti-IFN-␥ was amplified using the same procedure.
In vitro expression of murine IFN-␥ dvHSV/MuIFN-␥ was used to transfect Rous sarcoma virus (RSV) mouse glioma cells (provided by the Kihara Institute for Biological Research) cultured in Dulbecco's MEM (Life Technologies) supplemented in 10% fetal calf sera at 37°C in 5% CO 2 . The in vitro expression of murine IFN-␥ in RSV cells was examined by immunohistochemical staining by the standard avidin-biotin complex (ABC) method 23 using a Vectastain ABC kit (Vector Laboratories, Burlingame, Calif) with anti-murine rat IFN-␥ monoclonal antibody (mAb) (Upstate Biotechnology, New York, NY). The negative control study was performed with normal mouse sera (Chemicon International, Temecula, Calif) instead of the mAb. The percentage Ϯ SD of positive staining cells among 1000 cells was determined under magnification. In vitro growth inhibition of RSV cells treated with dvHSV/MuIFN-␥ RSV cells were transfected with 1 ϫ 10 6 PFU/mL of dvHSV/ MuIFN-␥ at three levels of multiplicity of infection (MOI): 0.5, 0.1, and 0.02; these levels were calculated from the helper virus titer. To make cell growth curves, cultured cells were floated in single suspension and treated with trypsin; the number of viable cells was measured. The growth inhibition of RSV cells by dvHSV/MuIFN-␥ was assessed from cell growth curves. As a control, cultured RSV cells transfected at the same MOI with the HSV-defective vector in which dvHSV/Mu.anti-IFN-␥ had been inserted were measured using trypan blue. The numbers of viable RSV cells in duplicate wells were averaged. As another control, nontreated RSV cells were measured using trypan blue. Subsequently, the cell growth curves were generated. In addition, the quantitation of murine IFN-␥ levels in RSV cell culture supernatants at 24, 48, and 72 hours after the addition of medium containing 1 ϫ 10 6 PFU/mL of dvHSV/ IFN-␥ was measured using the InterTest-␥ mouse IFN enzyme-linked immunosorbent assay (ELISA) kit (Genzyme, Cambridge, Mass) with an average of duplicates.
Effectiveness of dvHSV/MuIFN-␥ against subcutaneously (s.c.) implanted RSV tumors RSV cells (1 ϫ 10 6 ) suspended in 0.1 mL of saline were implanted in a femoral s.c. region of nude mice (BALB/c-nu/nu Sk, Japan SLC, Hamamatsu, Japan). At 2 weeks after the implantation, 50 L of MEM containing 5 ϫ 10 6 PFU/mL of dvHSV/MuIFN-␥ was injected into the center of the formed RSV tumor (ϳ10 mm in diameter) with one-shot injection using a microinjector. At 3 days after the vector injection, the tumor was removed, fixed with a solution of 4% formaldehyde and 10% methanol, and embedded in paraffin. After 10-m thin sections had been made, a standard hematoxylin-eosin staining procedure was performed. The immunohistochemical stain using anti-murine IFN-␥ mAb (Upstate Biotechnology) was performed by the ABC method. The negative control stain was performed with normal rat sera instead of anti-murine IFN-␥ rat mAb. In addition, infiltrating natural killer (NK) cells and macrophages in s.c. implanted RSV tumors were examined with immunohistochemical studies that were performed by the ABC method using anti-asialo GM1 (rabbit) (Wako Pure Chemical Industries, Osaka, Japan) for NK cells and adsorbed rabbit anti-mouse macrophage (Inter-Cell Technologies, Hopewell, NJ) for macrophages. 23 The percentage Ϯ SD of positive staining cells among 1000 cells was determined under magnification. The negative controls of immunohistochemical studies were performed with normal rabbit sera (Chemicon International).
Ex vivo gene transfer with dvHSV/MuIFN-␥
Murine IFN-␥ gene transfer and the secretion of murine IFN-␥ from RSV cells were confirmed by ELISA as described previously. At 24 hours after 15, 30, 60, and 120 minutes of treatment with dvHSV/MuIFN-␥ having 1 ϫ 10 6 PFU/mL at 37°C in 5% CO 2 , the quantitation of mouse IFN-␥ levels in RSV cell culture supernatants was examined (Fig 4) .
Subsequently, RSV cells (1 ϫ 10 6 ) were incubated for 1 hour at 37°C in 0.1 mL of medium containing dvHSV/MuIFN-␥ having 1 ϫ 10 6 PFU/mL (5% CO 2 ). Next, the treated RSV cells were implanted into a right femoral s.c. region of C3H mice (C3H/HeN Jcl, Japan SLC). After 1 month, the mice were sacrificed and observed pathologically to determine whether or not the treated RSV cells had been rejected. In addition, treated RSV cells were implanted into a right femoral s.c. region and nontreated RSV cells were implanted into a left femoral s.c. region in another group of five mice. Similarly 1 month later, these five animals were sacrificed and observed pathologically to determine whether or not the cells had been rejected. In a control group, RSV cells treated with dvHSV/ Mu.anti-IFN-␥ were used. 
Blocking of NK cell activity
Using anti-asialo GM1 (rabbit) (Wako Pure Chemical Industries) to block NK activity, 24 the endogenous immune effect was examined. A total of 100 L of anti-asialo GM1 (at a concentration of 10 mg/mL) was injected into the peritoneal space of mice that had been implanted with RSV cells treated with dvHSV/MuIFN-␥ into a femoral s.c. region. In addition, this reagent was injected into the peritoneal space of other mice that had been implanted with RSV cells treated with dvHSV/Mu.IFN-␥ into a femoral s.c. region and implanted with nontreated RSV cells into the contralateral region. After 1 month, we determined whether or not the implanted RSV cells had been rejected.
Statistical analysis
Comparisons within groups and intergroup comparisons were made using the Student t test. The level of significance for all tests of comparison was P Ͻ .05.
RESULTS
In vitro expression of murine IFN-␥ and growth inhibition of RSV cells by dvHSV/MuIFN-␥
At 3 days after transfection with dvHSV/MuIFN, RSV cells showed a high level of expression of murine IFN-␥ in their cytoplasm (Fig 2) . Growth inhibition of cultured RSV cells bearing dvHSV/MuIFN-␥ was significantly shown at every dvHSV/MuIFN-␥ concentration when compared with control group values. When the dvHSV/ MuIFN concentration was at an MOI of 0.5, 0.1, and 0.02, the growth of cultured RSV cells was significantly lower than that of the controls (P Ͻ .01). However, RSV cells transfected with dvHSV/Mu.anti-IFN-␥ also showed growth inhibition in vitro in comparison with the growth of nontreated RSV cells (P Ͻ .05). This result suggested cell toxicity of the HSV-defective vector itself as well as growth regression of RSV murine glioma cells by dvHSV/MuIFN-␥ (Fig 3) . The quantitation of mouse IFN-␥ levels in RSV cell culture supernatants at 24, 48, and 72 hours after the addition of medium containing 1 ϫ 10 6 PFU/mL of dvHSV/IFN-␥ is shown in Figure  4A . The result revealed that the RSV culture medium after the addition of dvHSV/IFN-␥ contained a high level of murine IFN-␥.
Effectiveness of dvHSV/MuIFN-␥ against s.c. implanted mouse glioma RSV tumors When dvHSV/MuIFN-␥ was injected into the RSV tumor at 2 weeks after the implantation, intratumoral (i.t.) necrosis was distinctly found 3 days after the injection; subsequently, tumor regression was observed. In addition, immunohistochemical study revealed that the cells around the sites of i.t. necrosis showed positive staining for murine IFN-␥ (Fig 5) . The percentage of murine IFN-␥-positive cells among 1000 cells was 14.6 Ϯ 5.2%. Of the infiltrating cells in s.c. implanted tumors, 15.7 Ϯ 3.7% were positively stained for anti-asialo GM1 antibody (Ab) and 12.0 Ϯ 4.5% were positively stained for anti-macrophage Ab (Fig 6) . Alternatively, i.t. central necrosis was only observed in a small area in control tumors in which dvHSV/Mu.anti-IFN-␥ was or was not transfected.
Effect of RSV cells bearing murine IFN-␥ gene on the immune system of the host
The secretion of murine IFN-␥ from RSV cells was confirmed by ELISA. At 24 hours after 15, 30, 60, and 120 minutes of treatment with dvHSV/MuIFN-␥ at 37°C in 5% CO 2 , the quantitation of mouse IFN-␥ levels in RSV cell culture supernatants resulted in 253.5-288.0 ng/mL (Fig 4) ; the significant difference among the treatment durations with dvHSV/MuIFN was not found.
When RSV cells treated with dvHSV/MuIFN-␥ were implanted into a right femoral s.c. region of nude mice (BALB/c-nu/nu Sk) or C3H mice (C3H/HeN Jcl), the implanted mouse glioma RSV cells were rejected. In addition, when 1 ϫ 10 6 treated cells were implanted into a femoral s.c. region on one side and the same number of nontreated cells were implanted into a contralateral femoral s.c. region in another group of mice, the implanted RSV cells were rejected bilaterally. The control group used with dvHSV/Mu.ant-IFN-␥ at the same PFU did not show a rejection of implanted mouse glioma RSV cells.
The blocking of NK activity using anti-asialo GM1 revealed that not all implanted RSV cells (nontreated or treated with dvHSV/MuIFN-␥) were rejected (Table 1) .
DISCUSSION
The HSV-defective vector was termed "amplicon" to delineate the fact that multiple copies of a DNA sequence of interest can be amplified in a head-to-tail arrangement in concatemeric defective virus genomes; in addition, this vector has a far greater packaging capability (Ն15 kb) than either the adeno-associated viral vector (5 kb) or adenoviral vector. Therefore, the HSV-defective virus vector can be used to introduce foreign genes into eukaryotic cells. This finding is in contrast to HSV whole-virus vectors. HSV amplicon vectors use the function of their helper virus to enter, replicate, and express genes in a variety of cells both in vitro and in vivo, depending upon the helper virus and the promoter used in the construct. Because the amplicon-defective genomes are packaged within HSV particles, and because HSV has a wide host range, the HSV amplicon can transfer genes into many types of cultured cells. In particular, an advantage of the HSV-defective virus vector is the efficiency of neuronal infection and rapidity of expression. The HSV-defective vector is valuable in establishing that a viral vector approach can complement more established methods to investigate neuronal physiology, characterize the regulation of gene expression in the brain, generate novel genetic models of neurological diseases, and show promise for gene therapy in the nervous system. In our HSV-defective vector system, the helper virus (tsk) is thermosensitive and can proliferate only at 31°C. This safety feature prevents in vivo proliferation of the HSV-defective vector.
In our HSV-defective vector, the human CMV immediate early promoter drives the expression of the murine IFN-␥ gene. IFN-␥, which is produced in nature by activated T lymphocytes and NK cells, is primarily a multifunctional rather than an antiviral cytokine. It plays an important role in host-defense mechanisms, including immune responses against neoplasms, in which it attacks tumor cells both indirectly and directly. Therefore, IFN-␥ is an important cytokine in the therapeutic approach to cancer. 11 The antitumor activity of IFN-␥ has not been fully elucidated. A direct inhibitory effect on cell proliferation is a representative biological activity of IFN-␥. An i. Implanted RSV cells bearing dvHSV/MuIFN-␥ were rejected. The rejection was found in both nude and normal (C3H) mice. In addition, when nontreated cells and cells treated with dvHSV/MuIFN-␥ were implanted bilaterally in femoral s.c. regions at the same time, the bilaterally implanted RSV cells were rejected. Moreover, when NK activity was inhibited with anti-asilo GM1 Ab, rejection of the implanted RSV cells with or without dvHSV/MuIFN-␥ treatment was not observed. These data demonstrate that T and B cells are not involved in the elimination of tumors.
Local i.t. injection of dvHSV/MuIFN-␥ may be effec- 
